Pegfilgrastim Biosimilar Market By Product Class (Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-inflammatory Agents, and Other Product Classes), By Applications (Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, Oncology, and Other Applications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region - Market Trends, Analysis, and Forecast till 2030

Pegfilgrastim Biosimilar Market accounted for USD 2765 Million in 2020 and is estimated to be USD 16580.8 Million by 2030 and is anticipated to register a CAGR of 19.8%.

Filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, is PEGylated to create Pegfilgrastim. Amgen Inc originally introduced pegfilgrastim as Neulasta. Pegfilgrastim biosimilars were later introduced to the market. Pegfilgrastim is a supportive oncology medication used to treat neutropenia caused by chemotherapy and/or radiotherapy in cancer patients.

With more than ten pegfilgrastim biosimilars on the market and another five in the works, the pegfilgrastim biosimilar market is projected to grow in the future. On the whole, the COVID-19 pandemic has had a minor impact on the pegfilgrastim market. COVID-19 has sped up clinical trial processes in general, but it is not expected to have a significant impact on regulatory approval processes in the near future. 

Academic and Research organizations in this industry through partnerships will drive the growth of the Market

Strategic alliances are helping companies in the pegfilgrastim biosimilar sector improve their product innovation. Companies are developing novel products and sharing skills and experience with other companies to maintain their place in an increasingly competitive market. While firms have traditionally partnered with one another as well as academic and research organisations in this industry through partnerships, in- or out-licensing agreements, this tendency has accelerated in recent years. Fulphila, produced jointly by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be authorised by the FDA in July 2018. Biocon Biologic Ltd. and the Clinton Health Access Initiative (CHAI) announced a collaboration deal in February 2021 to expand their lifesaving cancer biosimilars in more than 30 African and Asian countries. The collaboration represents a critical step forward in the delivery of sophisticated cancer medicines.

Pegfilgrastim Biosimilar Market is segmented based on product class, application, distribution channel and region.

On the basis of Product Class, the Pegfilgrastim Biosimilar Market is segmented into Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-inflammatory Agents, and Other Product Classes. Based on Application, the target market is segmented into Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, Oncology, and Other Applications. Based on Distribution Channel, the target market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Insights:

On region the Pegfilgrastim Biosimilar Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Pegfilgrastim biosimilars market in North America is expected to grow at a considerable CAGR over the forecast period. The high frequency of chronic diseases, such as cancers, as well as increased investment in research and development activities by the key players, are the main drivers driving the expansion of the studied market in the region.  For instance, According to Globocon 2020, in 2020, there are 2,281,658 new cancer cases diagnosed in the United States, with 612,390 fatalities. Breast cancer had the greatest incidence of all malignancies, with 253,465 cases, followed by lung (227,875), prostate (209,512), and colon cancer (101,809). Furthermore, according to a study published in Biosimilar Development 2020, the majority of biosimilars are injectables that must be administered to patients by a clinician. Due to the high risk of SARS-CoV2 viral transmission, most hospitals and clinics in the United States have banned physical consultations.

Pegfilgrastim Biosimilar Market Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the Pegfilgrastim Biosimilar Market report based on product class, application, distribution channel and region. 

Pegfilgrastim Biosimilar Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The market for pegfilgrastim biosimilars is very concentrated and competitive. This biosimilar was created by a number of small and large pharmaceutical businesses. Coherus Biosciences, Mylan N.V., Biocon, and Novartis AG are some of the major companies in the market (Sandoz). These firms have launched pegfilgrastim biosimilars and are bolstering their global market position with partnerships and collaborations. Pfizer Inc, Green Cross Corp, Accord Healthcare, Intas Pharmaceuticals Ltd, and Zydus Cadila are among the market's other participants. These companies are concentrating on strategic collaborations and partnerships, as well as research and development, in order to develop novel biosimilar platforms. Most of the market players are adopting various growth strategies, such as acquisitions, partnerships, and new product launches, to secure the position in the global market. For instance, in December 2020, Coherus filed FDA 351(K) application for its CHS-1420, a biosimilar of adalimumab, and the regulatory decision is expected by Q4 of 2021.

• Novartis AG
• Pfizer Inc.
• Amgen Inc.
• Coherus Biosciences Inc.
• Mylan NV (Viatris Inc.)
• Samsung Bioepis Co. Ltd